Class A Ordinary Shares $0.000273235 nominal value
- Symbol
- KNSA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Kiniksa Pharmaceuticals International, plc
KNSANASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On July 28, 2026, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description No.…
Press release in this filing
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution →Company context
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.
Current securities
Registered securities in this filing
Kiniksa Pharmaceuticals International, plc · 8-K · Filed 2026-07-28
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition
On July 28, 2026, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Description
No.
────────────────────────────────────────────────────────────────────────────────────────────────────────
99.1 Press Release issued by Kiniksa Pharmaceuticals International, plc, dated July 28, 2026
104 Cover Page Interactive Data File (embedded within the inline XBRL document)
Filed exhibits (1)
EX-99.1 2 knsa-20260728xex99d1.htm EX-99.1 Exhibit 99.1 Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution - ARCALYST® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth - - ARCALYST 2026 expected net product revenue increased to $980 - $995 million - - KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 - - KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients - - Conference call and webcast scheduled for 8:30 am ET today - London - July 28, 2026 - Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported second quarter 2026 financial results and recent portfolio execution. “In the second quarter, Kiniksa continued to drive growth in new and repeat prescribers of ARCALYST in recurrent pericarditis, which led to a meaningful increase in patients on therapy. As a resu…
Open exhibit ↗